A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants

Eli Lilly and Company

Summary

The main purpose of this study is to investigate the effects of where Eloralintide is subcutaneously (SC) injected into the body and to investigate how the body processes an intravenous (IV) dose of Eloralintide. Blood tests will be performed to investigate how the study drug affects the body. For each participant, the study will last about 12 weeks and will include a stay in the Clinical Research Unit (CRU) lasting 6 nights.

Eligibility

Age range: 18–65 years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation * Are 18 to 65 years of age inclusive, at the time of signing the informed consent. * Have a body mass index (BMI) within the range of 23.0 to 40.0 kilograms per square meter (kg/m²), inclusive. * Have had self-reported stable weight for the 3 months prior to screening, that is, less than 5 percent (%) body weight change. Exclusion Criteria: * Have known allergies to related compounds of eloralintide, or any of the components of the formulations. * Have been diagnosed with Type 1 or Type 2 diabetes mellitus. * Hav…

Interventions

Drug
Eloralintide
administered SC
Drug
Eloralintide
administered IV

Locations (2)

ICON
Salt Lake City, Utah
801-269-8200
Lilly Centre for Clinical Pharmacology
Singapore
6564139930

A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants

Summary

Eligibility

Interventions

Locations (2)

Compensation

Run this study?

Details

Conditions